Burcu Aslan
Houston,TX
Summary
Versatile clinical research professional knowledgeable about coordinating patient information, laboratory samples and compliance documents for diverse clinical trials. Highly organized and thorough with good planning and problem-solving abilities. Certified in [Area].
Overview
9
9
years of professional experience
1
1
Certification
Work History
Graduate Research Assistant
UT MD Anderson Cancer Center
- Enhanced research quality by conducting thorough literature reviews and synthesizing findings.
- Streamlined data analysis processes for improved efficiency and accuracy in research results.
- Contributed to the development of research proposals, securing funding for critical projects.
- Collaborated with multidisciplinary teams to advance research objectives and achieve project milestones.
- Mentored undergraduate students, providing guidance on research methodologies and techniques.
- Developed comprehensive reports, effectively communicating complex research findings to diverse audiences.
- Managed multiple research projects simultaneously, ensuring timely completion and adherence to high-quality standards.
- Presented research findings at conferences and workshops, fostering professional growth and collaboration within the academic community.
- Assisted in manuscript preparation, contributing to the publication of influential articles in peer-reviewed journals.
- Assisted faculty members in preparing grant applications by gathering relevant data and drafting supporting documents.
- Reviewed and synthesized relevant research articles to inform the development of research questions and hypotheses.
Clinical Research Coordinator
UT
2023.01 - Current
- Enhanced patient safety by meticulously monitoring and documenting adverse events during clinical trials.
- Streamlined data collection processes for increased efficiency and accuracy in study results.
- Coordinated with cross-functional teams to ensure timely completion of clinical trial milestones.
- Improved recruitment rates by developing and implementing effective patient outreach strategies.
- Facilitated clear communication between principal investigators, sponsors, and study participants for seamless trial execution.
- Trained new team members on essential clinical research protocols and procedures, promoting a culture of continuous learning.
- Conducted thorough literature reviews supporting the development of innovative study designs and methodologies.
- Assisted in drafting comprehensive research reports summarizing findings, conclusions, and recommendations for further action.
- Worked with principal investigator and sponsors to facilitate daily trial activities and comply with research protocols.
- Collected data and followed research protocols, operations manuals, and case report form requirements.
- Screened patient records, databases, and physician referrals to identify prospective candidates for research studies.
- Gathered, processed, and shipped lab specimens.
Instructor
The University of Texas MD Anderson Cancer Center
2020.03 - Current
- Experimental Therapeutics
Research Fellowship
University of Texas MD Anderson Cancer Center
2015.03 - 2020.02
Education
PhD - Biomedical Sciences
University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences
Houston, TX01.2014
M.S. - Nanotechnology & Nanomedicine
Hacettepe University
01.2009
BS - Biology
Hacettepe University
01.2007
Skills
- Research Experience
- Specimen Collections
- Research SOPs Understanding
- Data Analysis
- Critical Thinking
- Study Monitoring
- Team Collaboration
- Attention to Detail
- Time Management
- Clinical Research Ethics
Office Address
1901 East Rd., Unit 1950, Houston, TX, 77054
Office Phone
713-794-4539
Office Email
baslan@mdanderson.org
Current Appointments
03/01/2020, Present, Instructor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
Postgraduate Training
03/01/2015, 02/29/2020, Research Fellowship, University of Texas MD Anderson Cancer Center
Faculty Academic Appointments
03/01/2020, Present, Instructor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
Honors And Prizes
- 2019, Clyde H. Wright Memorial Fund Travel Award, $1000, The University of Texas MD Anderson Cancer Center
- 2015, Poster Presentation Winner, $750, The University of Texas MD Anderson Cancer Center
Book Chapters
- Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells, Aslan B, Ayres ML, Gandhi V, Methods Mol Biol, 19-25, United States of America
- Chitosan Nanoparticles for miRNA Delivery, Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Methods Mol Biol, 219-230, United States of America
- Chitosan nanoparticles, Aslan B, Han HD, Lopez-Berestein G, Sood AK, Encyclopedia of nanotechnology, United States of America, 2012
Patents
Dual Assembly Nanoparticles, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, 15/738180, United States of America
Degrees
PhD
Publications
- Journal Publications - Original research, Curing CLL: one clone at a time, Aslan B, Tantawy SI, Gandhi V, Blood Adv, 05/09/2023, 7, 9, 1926-1928, 36355806
- Journal Publications - Original research, Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia, Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V, Blood Cancer J, 05/01/2022, 12, 5, 80, 35595730
- Journal Publications - Original research, Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase, Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V, Haematologica, 01/01/2022, 107, 1, 292-297, 34498444
- Journal Publications - Original research, Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL, Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V, Blood Adv, 08/24/2021, 5, 16, 3134-3146, 34424317
- Journal Publications - Original research, ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer, Gorur A, Bayraktar R, Ivan C, Mokhlis HA, Bayraktar E, Kahraman N, Karakas D, Karamil S, Kabil NN, Kanlikilicer P, Aslan B, Tamer L, Wang Z, Cristini V, Lopez-Berestein G, Calin G, Ozpolat B, Mol Ther Nucleic Acids, 03/05/2021, 23, 930-943, 33614241
- Journal Publications - Original research, AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia, Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V, Clin Cancer Res, 07/15/2020, 26, 14, 3856-3867, 31937611
- Journal Publications - Original research, PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis, Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G, EBioMedicine, 02/01/2019, 40, 290-304, 30655206
- Journal Publications - Original research, Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer, Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G, EBioMedicine, 12/01/2018, 38, 100-112, 30487062
- Journal Publications - Original research, Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models, Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G, Mol Ther Nucleic Acids, 12/15/2017, 9, 251-262, 29246304
- Journal Publications - Original research, Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs, Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL, Oncotarget, 03/21/2017, 8, 12, 20145-20164, 28423620
- Journal Publications - Original research, MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase, Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B, Oncotarget, 02/14/2017, 8, 7, 11641-11658, 28036267
- Journal Publications - Original research, Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells, Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G, Cancer Res, 12/15/2016, 76, 24, 7194-7207, 27742688
- Journal Publications - Original research, The ZNF304-integrin axis protects against anoikis in cancer, Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G, Nat Commun, 06/17/2015, 6, 7351, 26081979
- Journal Publications - Original research, Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer, Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G, Clin Cancer Res, 05/01/2015, 21, 9, 2127-2137, 25595279
- Journal Publications - Original research, Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma, Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G, Mol Cancer Ther, 11/01/2014, 13, 11, 2583-2594, 25193509
- Journal Publications - Original research, Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery, Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G, Clin Cancer Res, 04/01/2013, 19, 7, 1806-1815, 23386691
- Journal Publications - Review articles, Nanotechnology in cancer therapy, Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G, J Drug Target, 12/01/2013, 21, 10, 904-913, 24079419
Certification
Adverse Events: Common Terminology Criteria for Adverse Events (V5)
Assessment, Recording and Reporting of Adverse Events
Fundamentals of Clinical Research
Essential Documents
New user training- CORe and PDMS
OneConnect-for Research Study Team Members
International Conference on Harmonization (ICH) E6 Good Clinical Practice Guidelines
Protocol Writing Tips
Source documentation
Clinical Research audit program
Data management in clinical trials
FDA Audits
Clinical Research Audit Program
Introduction to Informed consent
Timeline
Clinical Research Coordinator
UT
2023.01 - Current
Instructor
The University of Texas MD Anderson Cancer Center
2020.03 - Current
Research Fellowship
University of Texas MD Anderson Cancer Center
2015.03 - 2020.02
Graduate Research Assistant
UT MD Anderson Cancer Center
PhD - Biomedical Sciences
University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences
M.S. - Nanotechnology & Nanomedicine
Hacettepe University
BS - Biology
Hacettepe University
Adverse Events: Common Terminology Criteria for Adverse Events (V5)
Assessment, Recording and Reporting of Adverse Events
Fundamentals of Clinical Research
Essential Documents
New user training- CORe and PDMS
OneConnect-for Research Study Team Members
International Conference on Harmonization (ICH) E6 Good Clinical Practice Guidelines
Protocol Writing Tips
Source documentation
Clinical Research audit program
Data management in clinical trials
FDA Audits
Clinical Research Audit Program
Introduction to Informed consent
Similar Profiles
Caddie Laberiano FernandezCaddie Laberiano Fernandez
Research Scientist at UT MD Anderson Cancer CenterResearch Scientist at UT MD Anderson Cancer Center
SHEILA CASTROSHEILA CASTRO
Clinical Nurse at UT MD Anderson Cancer CenterClinical Nurse at UT MD Anderson Cancer Center
SONIA DAVISSONIA DAVIS
OFFICE MANAGER at UT MD ANDERSON CANCER CENTEROFFICE MANAGER at UT MD ANDERSON CANCER CENTER